Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Augusta University

Status and phase: Terminated; Phase 1

Conditions: Malignant Mesothelioma; Urothelial Carcinoma; Non-squamous Non-small-cell Lung Cancer; Non Small Cell Lung Cancer

Treatments: Drug: Cabozantinib; Drug: Pemetrexed

Study type: Interventional

Funder types: Other

Identifiers

NCT04173338

IST-65

Details and patient eligibility

About

This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.
• 18 years or older.
• At least one prior chemotherapy before entering in this trial.
• Not pregnant or breastfeeding.

Exclusion criteria

• Prior treatment with cabozantinib.
• Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study).
• History of bleeding disorder/bleeding history within 12 weeks before first study treatment dose.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

9 participants in 1 patient group

Cabozantinib + Pemetrexed

Experimental group

Description:

Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.

Treatment:

Drug: Pemetrexed

Drug: Cabozantinib